Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Thoracic 1Gynecologic 1Dermatologic 1

Conditions

Multiple Myeloma 2Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × lorvotuzumab mertansine × Clear all
NCT00346385 2015-03-26

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

ImmunoGen, Inc.

Phase 1 Completed
97 enrolled
DermatologicGynecologicThoracic

Ovarian Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT00991562 2014-11-21

IMGN901 in Combination With Lenalidomide and Dexamethasone

ImmunoGen, Inc.

Phase 1 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00346255 2013-04-23

IMGN901

ImmunoGen, Inc.

Phase 1 Completed
37 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡